{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T19:41:19Z","timestamp":1792611679128,"version":"4.5.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["contraceptionjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contraception"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1016\/j.contraception.2014.08.009","type":"journal-article","created":{"date-parts":[[2014,8,30]],"date-time":"2014-08-30T15:54:22Z","timestamp":1409414062000},"page":"71-75","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Increased exposure of norethindrone in HIV+ women treated with ritonavir-boosted atazanavir therapy"],"prefix":"10.1016","volume":"91","author":[{"given":"Barent N.","family":"DuBois","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Atrio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank Z.","family":"Stanczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3678-0443","authenticated-orcid":false,"given":"Ganesh","family":"Cherala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.contraception.2014.08.009_bb0005","series-title":"Women and health: today's evidence tomorrow's agenda","author":"World Health Organization","year":"2009"},{"key":"10.1016\/j.contraception.2014.08.009_bb0010","series-title":"Preventing mother-to-child transmission of HIV to reach the UNGASS and Millennium Development Goals World Health Organization","article-title":"PMTCT strategic vision 2010-2015","year":"2010"},{"key":"10.1016\/j.contraception.2014.08.009_bb0015","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2165\/00003088-200038010-00003","article-title":"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition","volume":"38","author":"Dresser","year":"2000","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.contraception.2014.08.009_bb0020","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/jac\/dkh029","article-title":"Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients","volume":"53","author":"Zeldin","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.contraception.2014.08.009_bb0025","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jsbmb.2007.09.025","article-title":"Identification of the human cytochrome P450 enzymes involved in the in vitro biotransformation of lynestrenol and norethindrone","volume":"110","author":"Korhonen","year":"2008","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1016\/j.contraception.2014.08.009_bb0030","series-title":"Medical eligibility criteria for contraceptive use","author":"Department of Reproductive Health","year":"2010"},{"key":"10.1016\/j.contraception.2014.08.009_bb0035","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/j.clinthera.2011.08.012","article-title":"Effect of vicriviroc with or without ritonavir on oral contraceptive pharmacokinetics: a randomized, open-label, parallel-group, fixed-sequence crossover trial in healthy women","volume":"33","author":"Kasserra","year":"2011","journal-title":"Clin Ther"},{"key":"10.1016\/j.contraception.2014.08.009_bb0040","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1046\/j.1365-2125.1998.00749.x","article-title":"Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers","volume":"46","author":"Ouellet","year":"1998","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.contraception.2014.08.009_bb0045","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1124\/dmd.110.037523","article-title":"Complex drug interactions of HIV protease inhibitors 1: inactivation, induction, and inhibition of cytochrome P450 3A by ritonavir or nelfinavir","volume":"39","author":"Kirby","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.contraception.2014.08.009_bb0050","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1111\/j.1471-0528.1980.tb04571.x","article-title":"Effects on sex hormone binding globulin of different oral contraceptives containing norethisterone and lynestrenol","volume":"87","author":"Odlind","year":"1980","journal-title":"Br J Obstet Gynaecol"},{"key":"10.1016\/j.contraception.2014.08.009_bb0055","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/S0140-6736(08)61081-8","article-title":"Once-daily atazanavir\/ritonavir versus twice-daily lopinavir\/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study","volume":"372","author":"Molina","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.contraception.2014.08.009_bb0060","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3111\/13696998.2011.554932","article-title":"Cost effectiveness of atazanavir-ritonavir versus lopinavir-ritonavir in treatment-naive human immunodeficiency virus-infected patients in the United States","volume":"14","author":"Broder","year":"2011","journal-title":"J Med Econ"},{"key":"10.1016\/j.contraception.2014.08.009_bb0065","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/0010-7824(78)90046-X","article-title":"A radioimmunoassay for norethindrone (NET): measurement of serum NET concentrations following ingestion of NET-containing oral contraceptive steroids","volume":"18","author":"Stanczyk","year":"1978","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2014.08.009_bb0070","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1097\/QAI.0b013e3182a9b3f1","article-title":"Effect of protease inhibitors on steady-state pharmacokinetics of oral norethindrone contraception in HIV-infected women","volume":"65","author":"Atrio","year":"2014","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.contraception.2014.08.009_bb0075","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1124\/jpet.104.075416","article-title":"Mechanism-based inactivation of CYP3A by HIV protease inhibitors","volume":"312","author":"Ernest","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.contraception.2014.08.009_bb0090","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0006-2952(99)00026-X","article-title":"HIV protease inhibitor ritonavir: a more potent inhibitor of p-glycoprotein than the cyclosporine analog SDZ PSC 833","volume":"57","author":"Drewe","year":"1999","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.contraception.2014.08.009_bb0095","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1124\/dmd.104.002931","article-title":"Atazanavir: effects on P-glycoprotein transport and CYP3A metabolism in vitro","volume":"33","author":"Perloff","year":"2005","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.contraception.2014.08.009_bb0100","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.maturitas.2008.11.013","article-title":"Classification and pharmacology of progestins","volume":"61","author":"Schindler","year":"2008","journal-title":"Maturitas"},{"key":"10.1016\/j.contraception.2014.08.009_bb0080","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/00000542-198461010-00006","article-title":"Effect of age, gender, and obesity on midazolam kinetics","volume":"61","author":"Greenblatt","year":"1984","journal-title":"Anesthesiology"},{"key":"10.1016\/j.contraception.2014.08.009_bb0085","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s00228-009-0777-6","article-title":"Variability in drug metabolizing enzyme activity in HIV-infected patients","volume":"66","author":"Jones","year":"2010","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.contraception.2014.08.009_bb0105","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/j.1365-2125.2012.04209.x","article-title":"Effect of the ethinylestradiol\/levonorgestrel combined oral contraceptive on the activity of cytochrome P4503A in obese women","volume":"74","author":"Edelman","year":"2012","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.contraception.2014.08.009_bb0110","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.contraception.2009.04.011","article-title":"Impact of obesity on oral contraceptive pharmacokinetics and hypothalamic\u2013pituitary\u2013ovarian activity","volume":"80","author":"Edelman","year":"2009","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2014.08.009_bb0115","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.contraception.2012.10.008","article-title":"Prolonged monitoring of ethinyl estradiol and levonorgestrel levels confirms an altered pharmacokinetic profile in obese oral contraceptives users","volume":"87","author":"Edelman","year":"2013","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2014.08.009_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.contraception.2014.06.033","article-title":"Correcting oral contraceptive pharmacokinetic alterations due to obesity: a randomized controlled trial","author":"Edelman","year":"2014","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2014.08.009_bb0125","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1046\/j.1528-1157.2003.55602.x","article-title":"Effect of topiramate or carbamazepine on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in healthy obese and nonobese female subjects","volume":"44","author":"Doose","year":"2003","journal-title":"Epilepsia"}],"container-title":["Contraception"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782414006398?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782414006398?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,30]],"date-time":"2018-09-30T01:29:07Z","timestamp":1538270947000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0010782414006398"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["S0010782414006398"],"URL":"https:\/\/doi.org\/10.1016\/j.contraception.2014.08.009","relation":{},"ISSN":["0010-7824"],"issn-type":[{"value":"0010-7824","type":"print"}],"subject":[],"published":{"date-parts":[[2015,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Increased exposure of norethindrone in HIV+ women treated with ritonavir-boosted atazanavir therapy","name":"articletitle","label":"Article Title"},{"value":"Contraception","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.contraception.2014.08.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}